Reports of Biochemistry
and Molecular Biology
Wed, May 1, 2024
[Archive]
Volume 9, Issue 1 (Vol.9 No.1 Apr 2020)
rbmb.net 2020, 9(1): 82-88 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Samadi E, Mirshahabi H, Motamed N, Sadeghi H. Prevalence of Occult Hepatitis B Virus Infection in Hemodialysis Patients Using Nested PCR. rbmb.net 2020; 9 (1) :82-88
URL: http://rbmb.net/article-1-433-en.html
URL: http://rbmb.net/article-1-433-en.html
Department of Microbiology and Virology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Abstract: (3561 Views)
Background: Occult hepatitis B infection (OBI) is defined as the lack of detectable HBsAg in serum, despite the presence of intrahepatic viral DNA, and low levels of covalently closed circular DNA (cccDNA). Since the hemodialysis patients are at a greater disadvantage if they are a carrier of Hep B, as it can lead to OBI this study was designed to determine the prevalence of OBI in hemodialysis patients residing in Zanjan, Iran.
Methods: We conducted an anti-HBc test (ELISA) on 166 HBsAg negative hemodialysis patient samples. OBI was evaluated using seropositive (anti-HBc and/or anti-HBs) and seronegative (anti-HBc and anti-HBs) using nested PCR.
Results: Out of the total hemodialysis patients sampled, the study consisted of 58.4% male and 41.6% female participants. The age of the study group ranged from 58.89±15.49, and had received approximately 28.27±27.43 years of dialysis. Additionally, 5.4% of patients had a history of blood transfusions, while 58.4% were vaccinated against the hepatitis B virus (HBV). Moreover, 23.5% patients were anti-HBc positive, while 76.5% patients tested negative. Lastly, 66.3% of the patients were positive for anti-HBs, whereas 33.7% were negative for anti-HBs. Overall, the study revealed that the prevalence of OBI was 6%, and HBV DNA was detected in 2.1% of individuals who were vaccinated against hepatitis B (p < 0.01).
Conclusions: Though no significant difference between the prevalence of OBI to the patients’ age, sex, duration of dialysis, or history of blood transfusion was identified, however, a strong correlation between the prevalence of OBI to HBV vaccination was found.
Methods: We conducted an anti-HBc test (ELISA) on 166 HBsAg negative hemodialysis patient samples. OBI was evaluated using seropositive (anti-HBc and/or anti-HBs) and seronegative (anti-HBc and anti-HBs) using nested PCR.
Results: Out of the total hemodialysis patients sampled, the study consisted of 58.4% male and 41.6% female participants. The age of the study group ranged from 58.89±15.49, and had received approximately 28.27±27.43 years of dialysis. Additionally, 5.4% of patients had a history of blood transfusions, while 58.4% were vaccinated against the hepatitis B virus (HBV). Moreover, 23.5% patients were anti-HBc positive, while 76.5% patients tested negative. Lastly, 66.3% of the patients were positive for anti-HBs, whereas 33.7% were negative for anti-HBs. Overall, the study revealed that the prevalence of OBI was 6%, and HBV DNA was detected in 2.1% of individuals who were vaccinated against hepatitis B (p < 0.01).
Conclusions: Though no significant difference between the prevalence of OBI to the patients’ age, sex, duration of dialysis, or history of blood transfusion was identified, however, a strong correlation between the prevalence of OBI to HBV vaccination was found.
Type of Article: Original Article |
Subject:
Microbiology
Received: 2019/12/13 | Accepted: 2020/03/1 | Published: 2020/05/19
Received: 2019/12/13 | Accepted: 2020/03/1 | Published: 2020/05/19
References
1. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49(4):652-7. [DOI:10.1016/j.jhep.2008.07.014] [PMID]
2. Fattovich G, Bortolotti F, Donato FJJoh. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335-52. [DOI:10.1016/j.jhep.2007.11.011] [PMID]
3. Lok ASF, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology.2004;39(3):857-61. [DOI:10.1002/hep.20110] [PMID]
4. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2(1):50-57. [DOI:10.7150/ijms.2.50] [PMID] [PMCID]
5. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani KJHm. Hepatitis B Virus infection in Iran: A systematic review. Hepatitis Monthly. 2008;8(4).
6. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial. 2008;21(5):440-6. [DOI:10.1111/j.1525-139X.2008.00437.x] [PMID]
7. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini‐Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?. 2001;34(1):194-203. [DOI:10.1053/jhep.2001.25172] [PMID]
8. Martinez MC, Kok CC, Baleriola C, Robertson P, Rawlinson WD. Investigation of occult hepatitis B virus infection in anti-hbc positive patients from a liver clinic. PLoS One. 2015;10(3):e0117275. [DOI:10.1371/journal.pone.0117275] [PMID] [PMCID]
9. Motta JS, Mello FC, Lago BV, Perez RM, Gomes SA, Figueiredo FF, et al. Occult hepatitis B virus infection and lamivudine‐resistant mutations in isolates from renal patients undergoing hemodialysis. J Gastroenterol Hepatol. 2010;25(1):101-6. [DOI:10.1111/j.1440-1746.2009.05972.x] [PMID]
10. Gutierrez-Garcia ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol. 2011;17(12):1538-42. [DOI:10.3748/wjg.v17.i12.1538] [PMID] [PMCID]
11. Chan T-M, Schwab SJ, Hirsch MS. Hepatitis B virus and dialysis patients. https://www.uptodate.com/contents/hepatitis-b-virus-and-dialysis-patients.
12. Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. 2010;15(2):137-45. [DOI:10.1111/j.1440-1797.2009.01268.x] [PMID]
13. Mohammadalizadeh AH, Ranjbar M, Seyf Aleslami SAR. The frequency of Hepatitis C in dailyse patients in HAMADAN EKBATAN hospital. 2002;7:27-34.
14. Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody: a multicenter study. Ther Apher Dial. 2010;14(3):349-53. [DOI:10.1111/j.1744-9987.2009.00798.x] [PMID]
15. Ramezani A, Aghasadeghi MR, Ahmadi F, Razeghi E, Eslamifar A, Banifazl M, et al. Isolated anti-hbc and occult HBV infection in dialysis patients. Nephrourol Mon. 2015;7(1): e22674. [DOI:10.5812/numonthly.22674] [PMID] [PMCID]
16. Esmat MM, Mohamed T, Zazi NAE. Occult Hepatitis b virus infection among Egyptian hepatitis c virus seropositive and seronegative hemodialysis patients in Sohag government, upper Egypt. Egyptian Journal of Medical Microbiology. 2015;24:113-118. [DOI:10.12816/0030403]
17. Minuk GY, Sun DF, Uhanova J, Zhang M, Caouette S, Nicolle LE, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005;42(4):480-5. [DOI:10.1016/j.jhep.2004.11.037] [PMID]
18. Aghakhani A, Banifazl M, Velayati AA, Eslamifar A, Ramezani AJTA, Dialysis. Occult hepatitis B virus infection in hemodialysis patients: a concept for consideration. 2012;16(4):328-333. [DOI:10.1111/j.1744-9987.2012.01072.x] [PMID]
19. Hashemi SJ, Hajiani E, Masjedizadeh A, Makvandi M, Shahbazian H, Shayesteh A, et al. A Case-Control Study on Occult Hepatitis B Infection in Chronic Hemodialysis Patients from South-West of Iran. 2015;20(1):135-40.
20. Rastegarvand N, Makvandi M, Samarbafzadeh A, Rasti M, Neisi N, Pouremamali A, et al. Molecular Characterization of Pre-Core/Core and S Region of Hepatitis B Virus in Hemodialysis Patients with Occult Hepatitis B Infection. Jundishapur J Microbiol. 2015;8(10):e23686. [DOI:10.5812/jjm.23686] [PMCID]
21. Neisi N, Makvandi M, Ali Samarbaf-Zadeh R. A study on genotypes of hepatitis B virus among hemodialysis patients in Khuzestan province. Jundishapur journal of microbiology. 2011;4(2):65-70.
22. Ramezani A, Aghasadeghi MR, Ahmadi F, Razeghi E, Eslamifar A, Banifazl M, et al. Isolated anti-HBc and occult HBV infection in dialysis patients. Nephro-urology monthly. 2015;7(1):e22674. [DOI:10.5812/numonthly.22674] [PMID] [PMCID]
23. Jardim RNCM, Gonçales NSL, Pereira JSF, Fais VC, Gonçales Junior FL. Occult hepatitis B virus infection in immunocompromised patients. Braz J Infect Dis. 2008;12(4):300-5. [DOI:10.1590/S1413-86702008000400008]
24. Abbasi A, Tajbakhsh R,Kabotari M, Zhand S, Tabarraei A. Occult Hepatitis B Virus Infection in Chronic Hemodialysis Patients in Panje-Azar Hospital, Gorgan. Medical Laboratory Journal. 2012;6(1):7-12.
25. Mustafa HNAR, Ahmad LM, Hassan ANL. Update on prevalence, diagnosis and treatment of hepatitis B virus. Faculty of Medicine Cairo University. 2005.
26. Fabrizi F, Dixit V, Bunnapradist S, Martin P. Meta‐analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther. 2006;23(8):1105-12. [DOI:10.1111/j.1365-2036.2006.02877.x] [PMID]
27. Fabrizi F, Messa PG, Lunghi G, Aucella F, Bisegna S, Mangano S, et al. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Alimentary pharmacology & therapeutics. 2005;21(11):1341-7. [DOI:10.1111/j.1365-2036.2005.02501.x] [PMID]
28. Zaki MES, Rafaat D, Eliwa A, Abdelsalam M. Occult hepatitis B among patients under hemodialysis at Mansoura University Hospitals: prevalence and risk factors. J Virol Antivir Res. 2014;3(1):1-6.
29. Fontenele AMM, Gainer JBF, e Silva S, Viana D, Cruz Santos MD, Salgado JV, et al. Occult hepatitis B among patients with chronic renal failure on hemodialysis from a capital city in northeast Brazil. Hemodial Int. 2015;19(3):353-9. [DOI:10.1111/hdi.12285] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
